Kyle Doherty

At a median follow-up of 13.9 months, patients with extra-pancreatic NETs treated with cabozantinib experienced a median progression-free survival of 8.3 months vs 3.2 months with placebo.

Results of from a subgroup of patients in the phase 2 C-144-01 study with advanced mucosal melanoma showed a clinically meaningful response to lifileucel after progression on immune checkpoint inhibitors.

Progression-free survival and overall survival data were maintained with fixed-duration venetoclax plus rituximab among patients with relapsed/refractory chronic lymphocytic leukemia

Patritumab deruxtecan showed clinically meaningful and durable efficacy in the phase 2 HERTHENA-Lung01 trial of patients with advanced EGFR-mutated non–small cell lung cancer.

Selecting and sequencing treatments in relapsed/refractory multiple myeloma involves balancing various factors due to limited historical data, as explained by Ajai Chari, MD, at the 2023 SOHO Annual Meeting.

Addition of ponatinib led to a higher rate of MRD-negative complete remission vs imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia.

Responses to fam-trastuzumab deruxtecan-nxki in patients with HER2-expressing tumors were durable in the phase 2 DESTINY-PanTumor02 trial.

At the second planned interim analysis of the phase 3 SWOG S1826, the primary progression-free survival end point crossed the protocol-specified statistical boundary.

In a phase 3 study, imetelstat has shown prolonged transfusion independence and hemoglobin increase in the relapsed or refractory myelodysplastic syndrome population.

Findings presented at a press briefing during the 2023 ASCO Annual Meeting revealed that the primary end point was met in the phase 3 NATALEE trial.

An artificial intelligence model has been shown to predict the risk of low and high distant recurrence in patients with endometrial cancer.

Treatment with the chimeric antigen receptor (CAR) T-cell therapy idecabtagene vicleucel is safe and effective for patients with relapsed/refractory multiple myeloma.

Findings from the phase 1/2 HERIZON trial showed HER-Vaxx plus standard-of-care chemotherapy to improve survival in patients with advanced gastric/gastroesophageal junction adenocarcinoma.

According to Benjamin P. Levy, MD, clinicians can use the information currently available to best decide the treatment sequence of immunotherapy vs targeted agents in locally advanced non–small cell lung cancer.

Trastuzumab deruxtecan demonstrated a clinically meaningful and statistically significant improvement in overall versus TDM-1 as well as a continued PFS benefit, according to Sara A. Hurvitz, MD.

Data presented at ESMO 2022 showed GSK3326595, aPRMT5 inhibitor, to display efficacy and safety signals consistent with those that were previously reported in advanced solid tumors.

DCC-3116 demonstrated safety and tolerability across various dose levels in patients with solid tumors harboring a RAS or RAF mutation, according to findings from a phase 1/2 trial presented at the 2022 ESMO Congress.

Naporafenib, in combination with several therapies, showed strong efficacy for patients with unresectable or metastatic melanoma.

The investigational carcinoembryonic antigen claudin 6–directed CAR T-cell therapy BNT211-01 displayed clinical activity in combination with a CLDN6-encoding mRNA vaccine in patients with CLDN6-positive relapsed/refractory advanced solid tumors.

Patients with treatment-naive myeloma treated with humanized IgGx CD38-targeted monoclonal antibody daratumumab in combination with lenalidomide and dexamethasone for at least 18 months had a overall survival benefit in the phase 3 MAIA study.

According to Conor E. Steuer, MD, patritumab deruxtecan showed promising clinical activity in heavily pretreated patients with advanced non–small cell lung cancer with or without identified variant genomic alterations.

IfIosfamide treatment improved event-free survival compared with topotecan plus cyclophosphamide in patients with relapsed/refractory Ewing sarcoma, phase 2/3 study results show.

First-line treatment with palbociclib plus letrozole demonstrated survival improvement vs letrozole monotherapy in patients with ER-positive/HER2-negative advanced breast cancer.

Both TROP-2 and Nectin-4 were shown to be highly expressed in urothelial cancer and variant histology bladder cancer, but not in patients with neuroendocrine histology.

IS-002 was shown to be safe, well-tolerated, and allow for enhanced intraoperative tumor detection in patients undergoing robotic prostatectomy, according to findings from a phase 1 study.

In patients with high-risk, muscle-invasive urothelial carcinoma treated in the adjuvant nivolumab lead to clinically meaningful improvements in disease-free survival compared with placebo.